Welcome to the struggling world of the small clinical laboratory. Here the adversaries don't play fair, the rules always change, and the costs always seem to go up. Who can be trusted? What can the lab do to stay above water? Turning a profit is the least of lab heir, Bill Dunlap's worries. Nevada's most cunning malpractice litigator is out for blood. UltraLabs sends a top M&A auditor to appraise the lab's value. To buy or not to buy? That is the question. Written for the industry's student and practitioner alike, the story establishes the framework for the lab's survival in an increasingly volatile and risky landscape. The book serves as a fictional case study of what happens when the lab's financial and quality controls suffer and what to do about it.